U.S. markets close in 1 hour 34 minutes

  • S&P 500

    4,515.52
    +29.06 (+0.65%)
     

  • Dow 30

    35,408.88
    +150.27 (+0.43%)
     

  • Nasdaq

    15,124.35
    +102.54 (+0.68%)
     

  • Russell 2000

    2,279.73
    +11.89 (+0.52%)
     

  • Crude Oil

    83.34
    +0.90 (+1.09%)
     

  • Gold

    1,770.00
    +4.30 (+0.24%)
     

  • Silver

    23.78
    +0.52 (+2.24%)
     

  • EUR/USD

    1.1647
    +0.0028 (+0.24%)
     

  • 10-Yr Bond

    1.6300
    +0.0460 (+2.90%)
     

  • GBP/USD

    1.3809
    +0.0082 (+0.59%)
     

  • USD/JPY

    114.2850
    -0.0270 (-0.02%)
     

  • BTC-USD

    63,337.36
    +1,406.14 (+2.27%)
     

  • CMC Crypto 200

    1,468.35
    +4.99 (+0.34%)
     

  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     

  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

The National Press Club Initiates Strict COVID-19 Protocol to Protect Attendees of the 2021 Fourth Estate Gala

·3 min read

All attendees required to show proof of vaccination, take COVID-19 PCR test on-site before entry

WASHINGTON, Oct. 19, 2021 /PRNewswire/ -- The National Press Club announced today that it will initiate a multi-step COVID-19 protocol to create the safest possible environment for in-person attendees at its upcoming Fourth Estate Award Gala on Wednesday, October 20th. The event will honor Lester Holt, award-winning journalist and anchor of NBC Nightly News and Dateline, who will receive an award for his significant contributions to the field of journalism.

NATIONAL PRESS CLUB LOGO. (PRNewsFoto/NATIONAL PRESS CLUB) (PRNewsfoto/National Press Club)
NATIONAL PRESS CLUB LOGO. (PRNewsFoto/NATIONAL PRESS CLUB) (PRNewsfoto/National Press Club)

Although the potential for COVID-19 transmission remains a risk for all in-person events, the Club will follow strict COVID-19 guidelines established by the District of Columbia. All attendees are asked to arrive early to prove vaccination status and receive Visby Medical's COVID-19 PCR test as administered by the laboratory service provider, BioQore Diagnostics. Attendees will also be required to wear masks during the event except when eating or drinking and observe basic social distancing and handwashing guidelines.

"It's important that people feel confident to attend live events once again, and we've done everything possible to create a COVID-safe environment for our guests at the Fourth Estate Gala," said National Press Club Executive Director Bill McCarren. "We're proud to honor Lester Holt for his decades of excellence in journalism, and we're grateful for recent advances in science and technology that allow us to do so."

NPC is using the Visby Medical COVID-19 PCR test, as administered by a nationally certified CLIA lab, is accurate and fast, with results available in less than 30 minutes. After the test is administered, guests will remain in a dedicated waiting area until their results are ready, and only those with a negative result will be admitted to the Gala.

"PCR testing is the gold standard in molecular diagnostics, including COVID-19 and other infectious diseases, but traditional PCR platforms require centralized labs with large equipment, a process that delays results," said Visby Medical Founder and CEO Adam de la Zerda, Ph.D.. "That unacceptable wait for accuracy motivated us to develop the first single-use palm-sized PCR platform to address both the COVID pandemic and epidemic of sexually transmitted infections."

The National Press Club looks forward to recognizing recipients of this year's awards and will continue to take all possible and necessary precautions to host COVID-safe events to ensure the health and wellbeing of its members and guests.

About the National Press Club
Founded in 1908, the National Press Club is the world's leading professional organization for journalists. The Club has 3,000 members representing nearly every major journalism organization and is a leading voice for press freedom in the United States and around the world.

PRESS CONTACT: Bill McCarren, wmccarren@press.org, (202) 662-7534

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-national-press-club-initiates-strict-covid-19-protocol-to-protect-attendees-of-the-2021-fourth-estate-gala-301403772.html

SOURCE National Press Club

Recommended Stories

  • Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test

    Atea Pharmaceuticals said Tuesday its Merck-rivaling antiviral Covid pill failed in a midstage test, leading AVIR stock to crash.

  • David v Goliath in The Race to Develop an Oral Therapy for COVID-19

    Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19 can agree on, is the urgent need for oral, pill-based treatments that are effective at halting disease progression, can get — and keep — people out of the hospital and can reduce mortality. One key group of COVID-19 patients who are in desperate need of treatment options are those moderately severe patients in hospital

  • 2 Biotech Stocks Set to Go Supernova Soon

    Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

  • United Therapeutics hits speed bump in its quest for new drug approval

    The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.

  • Vertex Unveils First Patient Results On Potential Diabetes Treatment

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D). VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The patient, who had suffered five potentially life-threatening hypoglycemic (low blood sugar) episodes in the year before the therapy, was injected with synthetic insulin-producing cells. After 90 days, the patient’s new cells

  • Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops

    Biogen and Ionis' approach to Lou Gehrig's disease flopped over the weekend, leading IONS stock to collapse to a five-year low Monday.

  • Why Edesa Biotech Shares Are Trading Higher Today

    Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings. The company said it believes EB05 regulates the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome, which is the leading cause of death in COVID-19 patients. "

  • 80% of Medicare beneficiaries don’t know this rule — or its penalty

    Failing to enroll in Medicare can lead to some steep penalties, and that’s just as true for Medicare Part D, which covers prescription drugs. Eight in 10 Medicare beneficiaries were not aware of the late enrollment penalty for Part D, according to a survey of more than 1,000 people from MedicareAdvantage.com. The penalty applies to people who do not have “creditable drug coverage” for 63 days.

  • Atea Pharma Stumbles in Race for a Covid Pill. The Stock Fell 76%.

    Public-health experts hope that a Covid-19 pill could be an affordable, convenient tool to reduce the human cost of the virus.

  • Business leaders support Biden’s vaccine mandate–but only if the rules are workable

    A recent survey found that most business executives support the vaccine and testing mandates, but have concerns over their implementation.

  • Pfizer CEO says he’s gotten a COVID vaccine booster shot and most of us will, too

    U.S. regulators 'will start moving [booster] recommendations to earlier ages,' predicts Albert Bourla.

  • Why Shares of MannKind Corporation Are Falling This Morning

    Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.

  • The Most Exciting Medical Breakthrough Of The Decade?

    Artificial intelligence is coming for the $11 trillion doctor industry, and it could change how you and your doctor interact for decades to come

  • The Most Common Places COVID Is Spreading Right Now (And Where It's Not)

    Curious what activities may be associated with higher COVID-19 transmission? Here's what data suggests.

  • 2 Best Biotech Stocks to Buy Right Now

    These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.

  • Biogen Stock Drops as ALS Trial Fails. Ionis Is Getting Hit Even Harder.

    Shares of the biotech companies are slumping after the failure of a trial for its treatment for amyotrophic lateral sclerosis.

  • Best and worst states for Medicare prescription drug prices

    Using Medicare Part B and D metrics, the analysis looked at 13 measures of prescription drugs categorized by cost, access, and quality, and ranked all 50 states and Washington, D.C.

  • Neovasc Receives FDA Approval for COSIRA-II Clinical Trial

    The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Neovasc Inc. (NASDAQ: NVCN) is a medical device company focused on developing, manufacturing, and marketing products for the cardiovascular market. Neovasc is a leading developer of minimally invasive transcatheter mitral valve replacement technologies as well as minimally invasive devices for the treatment of refractory angina. Refractory ang

  • Is Pfizer Stock A Buy As 'Open Season' Begins On Covid Booster Shots?

    Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?

  • Atea plunges after COVID-19 treatment fails to help patients in study

    Atea Pharmaceuticals Inc's experimental COVID-19 antiviral pill, being developed with Roche, failed to help patients with mild and moderate COVID-19 in a small study of mostly low-risk patients, driving the U.S. drugmaker's shares down more than 65% on Tuesday. The trial results puts Atea and Roche far behind U.S.-based Merck & Co Inc in the race to a pill to treat COVID-19. Atea is considering changing the target patient population for its larger, late-stage trial, making it more similar to the trial run for Merck's molnupiraivir.